-2.96%07-07“The whole tape ripped and it fell alone, down over 10% in four sessions. Cook himself said memory shortages will throttle the September quarter — this isn't mispricing, it's disclosure. Close the position; don't argue with a supply chain's calendar”
Technicals — It closed at $303.42, down 1.78%, falling on a day the Dow printed a record and the Nasdaq gained 2.1% — dismal relative strength. The four-session drawdown now exceeds 10%, taking price through the 20-day ($323.90) and 50-day ($309.52); the only structural support left is the 200-day at $278.24, still 8.3% below. RSI(7) at 26.7 is oversold while RSI(14) at 40.3 is not yet extreme — a technical bounce is due, but the trend has already broken.
Fundamentals — Q3 revenue of $109.4B rose 16% — the highest third quarter in company history — and EPS beat. But Q4 guidance of 9–11% growth implies roughly $113B against a $114.9B consensus. At 34.8x trailing earnings Apple is the most expensive name in this group, paired with 14.2% revenue growth and a 48.7% gross margin; in a rising memory-cost cycle that valuation offers no cushion. The Street's $328.01 average target implies just 8.1% upside, the lowest of any deep-dive name here.
News — Apple posted its worst single-day decline in more than a year, falling as much as 7.35% intraday on 8/3. The core issue: Cook stated plainly that component shortages, memory chips above all, will keep constraining iPhone, Mac and iPad production through the September quarter while raising hardware costs. Barclays and GF Securities followed with downgrades. The irony is that the same memory inflation crushing Apple is what has been lifting MU and SNDK — one cycle, and the buyer of chips pays for the seller's feast.
Short-term · 1–3 weeks
NeutralSidelines
Closing the position this cycle — a defensive exit, not a stop-out on thesis. The long recorded on 7/29 has fallen from $340.08 to $303.42 as trend and fundamentals deteriorated together. Cook put a September-quarter timeline on the constraint; that's management guidance, not sentiment. RSI(7) at 26.7 will produce a bounce, but a bounce isn't a reversal, and 34.8x prices in no discount for a supply bottleneck. Reassess on the reaction at the $278.24 200-day.
Entry Sidelines; wait for a reaction at the 200-day near $278Stop —Target —
Long-term · months+
Neutral
The ecosystem and services moat is intact, and record Q3 revenue proves demand is healthy. But a rising memory-cost cycle will genuinely compress hardware margins, and 34.8x requires acceleration while guidance delivers the opposite.
If memory inflation runs into 2027, margin pressure exceeds current guidance
A 34.8x multiple is unsupported once growth decelerates toward 10%
Consensus upside of just 8.1% suggests the Street has already priced it in
Signal BacktestCumulative -2.96%price itself -7.35%0/1 closed trades wonprofitable since 07-09
07-07Long$312.66 → closed $303.4208-04-2.96%
Community Voices
WSB · Mentions rose from 24 to 89 but drew only 228 upvotes; the chatter is complaint, not accumulation — retail is still waiting for a price that stops fallingOriginal ↗
Institutional Views
华尔街共识 · 51 analysts average a $328.01 target, only 8.1% above spot, at a 1.50 rating that leans neutral — the narrowest upside among today's deep dives
Barclays · Downgraded on supply-chain challenges and margin headwindsSource ↗
-26.77%07-07“DRAM spot prices at a ten-year high while the stock trades a third below its June peak: the market isn't pricing today's cash flow, it's pricing CXMT's future capacity. Number one on WSB with 595 mentions — that kind of noise at that kind of level has never been a good omen”
Score7/10RSI(14) 44.1P/E TTM 18.8EPS growth TTM +697%vs June high -33.9%DRAM ASP $1.17 (10-year peak)
Technicals — It closed at $829.50, up just 0.79%, essentially flat on a day the Nasdaq gained 2.1% — clearly weak relative strength. Price sits below the 20-day ($903.93) and 50-day ($966.80) while remaining far above the 200-day ($521.31): the intermediate trend is intact, the short-term trend is not. RSI(14) at 44.1 is neutral, with the stock down 11.0% on the week and 20.4% on the month. ATR of $88.83 equates to roughly 10.7% daily range, among the highest of any large-cap here. The $800 round number is both psychological and technical support; below it the next meaningful level is near $700.
Fundamentals — Trailing revenue is up 167%, EPS up 697%, on a 72.6% gross margin — against a multiple of just 18.8x. That is the classic shape of a cyclical top: exploding earnings inflate the denominator and flatter the apparent P/E. DRAM average selling prices have reached a ten-year peak of $1.17, with DDR5 16Gb spot up 0.72% and DDR4 16Gb up 0.57% on 8/3. Management says supply tightness persists beyond 2027 and has signed a five-year pricing lock. The debate isn't about how good today's cash flow is — it's whether the market will pay for the next leg of the cycle.
News — Micron fell as much as 3.5% to $794.59 in early trading on 8/3 after reports on Chinese rival ChangXin Memory (CXMT) revived supply-risk fears, before scraping out a +0.79% close. This is a continuation of the same thread that drove the CXMT Shanghai-listing panic in the last brief. The central tension is stark: spot prices are rising while the stock falls, meaning investors are discounting the durability of future pricing rather than the strength of present demand.
Short-term · 1–3 weeks
NeutralSidelines
Maintaining last cycle's sidelines call: gaining only 0.79% on a broad-rally day is unambiguously negative relative strength when risk appetite is returning. An ATR of $88.83 means any entry absorbs 10%-scale intraday swings, while the CXMT capacity variable has neither a timeline nor hard data. The Street's 87.4% implied upside is seductive, but when analyst targets fight the tape, watch who is voting with actual money. Reassess only if $800 holds and price reclaims the 20-day at $903.93 on volume.
Entry Sidelines; wait for a decisive reaction at $800Stop —Target —
Long-term · months+
Neutral
Structural HBM and DRAM demand is real, and both spot pricing and the five-year lock support the tightness argument. But an 18.8x multiple rests on 697% EPS growth, and a low P/E near a cyclical earnings peak is a trap, not a discount.
The timing and scale of CXMT's capacity ramp remain entirely unknown
Once the cycle rolls, falling EPS turns 18.8x into 40x overnight
A 10.7% ATR makes position sizing punishing
Signal BacktestCumulative -26.77%price itself -19.64%0/2 closed trades wonprofitable since 07-10
07-07Long$984.75 → closed $853.207-17-13.36%
07-22Long$970.82 → closed $820.5307-29-15.48%
Community Voices
WSB · Mentions rocketed from 107 to 595 with 2,608 upvotes, holding the number one slot site-wide. The top of that leaderboard has never been a buy signal — it's a crowding alarmOriginal ↗
Institutional Views
华尔街共识 · 56 analysts average a $1,554.51 target, a striking 87.4% above spot, at a 1.15 rating near strong buy — the gap between the Street and the tape is today's loudest signal
-31.04%07-22“That candle at $1,000 finally buried the knife in the floor, and six sessions later it's up 27%. But 8/5 earnings is the next coin flip, and with an ATR near $200 you aren't buying the memory cycle — you're buying volatility”
Score8/10RSI(14) 43.2vs June high -45.3%YTD +427%ATR $198.21Earnings 8/5
Technicals — It closed at $1,288.03, up 6.03%. After bottoming at $1,015.89 on 7/29, the stock ripped 25.99% on 7/30 to $1,279.96, giving the $1,000 round number a live test it passed. Price remains below the 20-day ($1,486.57) and 50-day ($1,707.12) and sits 45.3% under the June high of $2,354.39, though far above the 200-day at $848.89. RSI(14) is a neutral 43.2. An ATR of $198.21 implies a 15.4% daily range — the most extreme volatility on the board, and any position must be sized as a wager rather than an investment.
Fundamentals — Trailing revenue is up 82.8% on a 56.0% gross margin, at a 44.8x multiple. Last quarter surging NAND prices plus AI-driven storage demand produced record revenue growth and materially better profitability, with the margin expansion showing effective cost pass-through. The stock is still up 427% year to date and 2,953.7% over one year — a base that forces any valuation discussion to start by acknowledging you are looking at a cyclical that has already run its primary advance.
News — SanDisk gained 6.03% on 8/3 (some feeds show +3.48%), extending its repair off the $1,000 support test as sentiment improved. The decisive event lies ahead: fiscal Q4 and full-year results land on 8/5, with the Street expecting strong year-over-year growth from AI and enterprise storage demand. From the $2,335 close on 6/25 to $1,015.89 on 7/29 the stock fell 56.49% — this print decides whether the bounce is a bottom or a way station.
Short-term · 1–3 weeks
NeutralSidelines
Staying sidelined. The $1,000 shelf did hold and a 27% six-day bounce is genuinely impressive, but entering ahead of the 8/5 print is a pure event bet — with an ATR of $198.21, a 20% earnings gap is routine rather than tail risk. Wait for the print, a clear gap direction, and a reclaim of the 20-day at $1,486.57 before committing to a signal worth booking.
Entry Sidelines; no participation before the 8/5 printStop —Target —
Long-term · months+
Neutral
Margin expansion from NAND pricing and AI storage demand is real, and 44.8x against 82.8% revenue growth is not absurd. But a 2,953% one-year gain says the market has fully priced the upcycle; what remains is a race between delivery and giveback.
A 15.4% daily range makes long-term holding psychologically expensive
A peak in NAND pricing ends the margin-expansion story simultaneously
Still 45% below the June high; the downtrend has not been technically invalidated
Signal BacktestCumulative -31.04%price itself -26.19%0/1 closed trades wonprofitable since 07-24
07-22Long$1,589.4 → closed $1,096.107-29-31.04%
Community Voices
WSB · Mentions rose from 58 to 221 for fifth place. Retail is loading up two days before the print — anyone entering here is betting on luck, not logicOriginal ↗
Institutional Views
华尔街共识 · 30 analysts average a $2,363.65 target, roughly 83.5% above spot, at a 1.32 rating leaning strong buy
0.00%07-10“Most companies announce a merger and rally; this one announced talks and lost 6.9%. When the market would rather you didn't buy anything, it's telling you it trusts your own pipeline more. Day one of a rumored deal is always the most expensive — wait until the talks say something”
Technicals — It closed at $157.97, down 6.88%, on 6.42x relative volume — a textbook news-driven volume break. Price sliced through the 20-day ($171.43), 50-day ($178.57) and 200-day ($184.31) in one session, leaving a complete bearish stack. RSI(7) at 22.5 is deeply oversold and RSI(14) at 32.3 is close behind, so a technical bounce is available — but the decline reflects a structural repricing on news rather than pure sentiment selling. The 52-week low at $141.77, 10.3% below, is the only clear support beneath.
Fundamentals — It trades at 23.9x trailing earnings with EPS up 17.0% but revenue growth of only 1.1% — the growth engine is visibly slowing, though a 73.9% gross margin remains excellent and a 1.94% yield offers a floor. The Street's $216.44 target implies 37.0% upside, among the widest discounts in today's deep dives. That gap says something specific: institutions believe the fundamentals are unchanged and only the deal-related uncertainty is new.
News — AstraZeneca plunged roughly 7.7% during Monday's US session on 8/3 (closing -6.88%) after the Financial Times reported merger talks with Bristol Myers Squibb on a deal worth close to $400B; Reuters confirmed preliminary contact through a person familiar, though neither company confirmed talks remain active. Investor pushback centered on three points: AstraZeneca's own organic growth and pipeline make the strategic logic questionable; antitrust risk is severe, since the combined oncology portfolio would likely be the industry's broadest; and integration would drag on the existing growth trajectory. Berenberg said shares would 'likely remain depressed.' Notably BMY rose 0.24% the same day — the would-be target was the calmer of the two.
Short-term · 1~3 weeks
NeutralSidelines
RSI(7) at 22.5 is tempting and 37% implied upside is substantial, but this is not a technical mispricing — the mere existence of merger talks is an open variable that cannot be priced. Berenberg put it plainly: shares stay depressed while it's unresolved. Taking a direction before there are answers on deal structure, consideration, and the antitrust path means paying for someone else's uncertainty. Wait for a statement.
Entry Sidelines; wait for the talks to either advance concretely or be called offStop —Target —
Long-term · months+
Neutral
A 73.9% gross margin, a deep solid-tumor pipeline and a 1.94% yield make for a solid defensive asset at an undemanding 23.9x. But 1.1% revenue growth shows organic momentum is fading, and if a $400B merger proceeds the company's entire risk profile is rewritten.
If the deal advances, antitrust review could run years and force divestitures
Revenue growth of just 1.1% puts more pressure on pipeline delivery than the market assumes
Price is below all three moving averages; trend repair will take time
Community Voices
StockTwits · A 5.63 trending score with the debate fixed on whether a $400B deal is strategy or panic — for once retail asked 'why buy at all' before the institutions didOriginal ↗
Institutional Views
华尔街共识 · 32 analysts average a $216.44 target, about 37.0% above spot, at a 1.33 rating leaning strong buy
Berenberg · Said shares will 'likely remain depressed' while the megadeal stays unresolvedSource ↗
-9.27%07-07“A record 480,000 deliveries bought a 27% monthly decline. A 299x multiple against -37.7% earnings growth isn't oversold, it's valuation doing exactly what it should. A 3.5% bounce changes none of those numbers”
Technicals — It closed at $322.08, up 3.49%, yet remains below the 20-day ($359.05), 50-day ($388.86) and 200-day ($411.06) — a thoroughly bearish stack. Price sits just 8.3% above the $297.38 52-week low after falling 24.7% on the month and 29.6% year to date. RSI(14) at 36.8 approaches oversold without reaching an extreme, and RSI(7) at 39.8 is similarly soft — technically this is not yet a level where selling is exhausted. Relative volume of 0.81 shows the bounce came on light participation, without confirming flows. ATR is $16.64.
Fundamentals — It trades at 299.2x trailing earnings with EPS down 37.7%, revenue up 11.8%, and a gross margin of just 18.9%. Last quarter brought record deliveries of 480,126 and record revenue of $28.24B, yet profitability disappointed — which is precisely the problem: volume is growing while profit shrinks. The Street's $376.83 target implies 17.0% upside on a 1.74 rating, the closest to neutral of any deep-dive name here, which says the institutions aren't sure either.
News — Tesla rose 3.49% with the tape on 8/3 without a standalone catalyst — the move came from optimism around the next-generation vehicle platform and a broader risk-appetite recovery. More consequential is a Wall Street Journal report that executives are weighing multiple divestiture paths for the China business, a major strategic variable for a company that treats China as a core manufacturing and demand base. Shares have fallen from a July high near $425 toward the $297.38 low, down 26.83% on the month.
Short-term · 1–3 weeks
NeutralSidelines
Maintaining sidelines. A 3.49% low-volume bounce on a day the Nasdaq gained 2.1% shows nothing in relative strength. A 299x multiple against -37.7% earnings growth means any 'oversold' discussion is happening on the wrong axis — multiple compression is the main story, and RSI at 36.8 isn't even oversold. The China divestiture report adds a new strategic variable that cannot be priced. Wait for the reaction at $297.38.
Entry Sidelines; the $297.38 52-week low is the only level worth watchingStop —Target —
Long-term · months+
Neutral
Record quarterly deliveries of 480,000 show demand is still growing, and a next-generation platform could reopen the growth runway. But an 18.9% gross margin with EPS down 37.7% shows scale is not producing profit, and 299x offers no support for that combination.
The China divestiture report touches its core manufacturing and demand base
At 299x with negative earnings growth, there is no valuation floor
A break of the $297.38 low would open fresh downside
Signal BacktestCumulative -9.27%price itself -24.27%0/1 closed trades won
07-07Long$419.77 → closed $380.8407-18-9.27%
Community Voices
StockTwits · A watchlist perennial that missed today's trending board. Tesla's most dangerous signal isn't retail complaining — it's retail no longer bothering to argueOriginal ↗
Institutional Views
华尔街共识 · 49 analysts average a $376.83 target, about 17.0% above spot, at a 1.74 rating that leans neutral — the most divided consensus among today's deep dives
Down 2.94% through the 50-day at $93.61 with RSI(7) at 36.3 weakening, as staples lost flows on a risk-on day. Closing the position; revisit once it reclaims the average.
Down 0.61% and pinned right at the 50-day at $68.76 with RSI(7) at 30.1, utilities have lost their allocation case to the twin headwinds of rates and risk appetite. Closing the position.
Below both the 50-day at $147.25 and 200-day at $141.61 with RSI(7) at 27.5 — oversold but structurally broken. WSB mentions doubling to 80 is noise, not support. Closing the position.
Up 2.93%, notably light versus its index weight on a 2.1% Nasdaq day, with RSI at 53.1 sitting right on the 50-day at $205.84. The 52.1% consensus upside is tempting but direction is unresolved; sidelines.
Up 1.78% and trailing the sector, still below the 50-day at $512.95 after a 8.1% weekly decline. At 159x, there's no margin of safety amid semiconductor dispersion; sidelines.
Up 5.68% but down 28.3% on the month with RSI still soft at 38.3, no moving-average history and no verifiable financials. The 99.2% consensus upside cannot be independently checked; sidelines.
Up 11.64% on the $1B-plus Reflection AI compute contract and neocloud sympathy, yet still below the 50-day at $224.11 with extreme volatility into the 8/12 print; sidelines.
Up 9.98% repairing the 20% post-earnings overreaction on 61% Q2 revenue growth and above-consensus Q3 guidance — but still below all three moving averages and down 20.3% on the month. A bounce is not a reversal; sidelines.
Up 4.86% to a fresh 52-week high of $315.42 as Wells Fargo raised its target to $500 from $320 — but RSI at 74.5 is overbought and consensus targets already sit 0.8% below spot. Chasing risks more than it offers; sidelines.
Up 6.72% on 8.42x relative volume with RSI at 66.4 reclaiming every moving average — but 2.6% revenue growth cannot sustain a rerating at this pace; sidelines.
The other side of the merger story gained just 0.24%, with RSI at 71.4 overbought and a $65.39 consensus target level with spot. As the would-be acquirer, the valuation gap is already closed; sidelines.
Down 6.97%: EPS of $3.19 beat while revenue of $7.07B missed $7.17B, Middle East RevPAR collapsed 43%, and Q3 guidance came in light. RSI(7) at 22.6 is oversold but the geopolitical variable is unresolved; sidelines.
Down 2.0% as risk appetite returned, breaking the 50-day at $274.58 and 200-day at $300.31 and now just 1.6% off its 52-week low as defensives rotate out; sidelines.
Down 3.39% through the 200-day at $836.10 with RSI(7) softening to 42.0, as the defensive pharma-distribution case temporarily lost the rotation; sidelines.
Up 28.22% on Prysmian's $95/share all-cash bid plus a Q3 beat. At $93.55 the stock sits just 1.5% below the offer, so the arbitrage is effectively closed; sidelines.
Up 2.67% to a 52-week high on the board's highest relative volume at 20.69x — but RSI at 84.9 is extremely overbought and the breakout's risk/reward has flipped; sidelines.
Up 4.63% to a $87.63 52-week high and 26.3% on the month on a clear CGM demand trend — but RSI at 72.6 is overbought and a pullback toward the 20-day near $80 would be a better entry; sidelines.
Up 3.18% to a 52-week high and 19.4% on the month with RSI still healthy at 64.6. The annuity book benefits from the rate backdrop, but there was no standalone catalyst today; sidelines.
Up 2.87% to a $41.03 52-week high with RSI at 64.3 — but the long-running user-growth problem is unresolved and the breakout lacks fundamental confirmation; sidelines.
Up 2.4% toward the $118.30 high with a healthy RSI of 60.5; life-science tools demand is recovering alongside CXO, but the move already reflects it; sidelines.
RSI(7) at 22.1 is deeply oversold after a 10.3% monthly decline, and industrial-gas cash-flow quality is high — but price is below every moving average with no stabilization signal; sidelines.
RSI(7) at 17.1 is the most oversold on the board after weekly and monthly declines of 17.8% and 20.4%. The auto-chip inventory cycle hasn't bottomed, and oversold isn't cheap; sidelines.
RSI(7) at 19.5 is extremely oversold after a 24.2% week, down 74% from its high and closing on the $33.88 low. The downtrend is intact and catching this knife is high-risk; sidelines.
Up 7.21% but down 19.2% on the week and 27.5% on the month, with RSI still oversold at 31.3 and only 11% above its 52-week low. The bounce lacks volume confirmation; sidelines.
Down 33.4% on the month and 41% from its high with RSI oversold at 31.8; the infrastructure contractor needs fresh data to restore backlog visibility; sidelines.
RSI(7) at 16.6 is the second-lowest on the board after weekly and monthly declines of 20.8% and 23.9%; there's no evidence the freight-brokerage cycle has bottomed; sidelines.
RSI oversold at 28.1 but only 4.4% above its 52-week low, below every moving average and down 10.3% on the month as defensives bleed in rotation; sidelines.
Down 35.4% on the month and 46% from its high with RSI oversold at 30.5, sitting just under the 200-day at $51.63; mature-node overcapacity is unresolved; sidelines.
Up 2.82% but with RSI at 28.0 among the lowest on the board, down 21.8% on the month and only 5.8% above its low, weakening alongside LII in the HVAC chain; sidelines.
Down 12.25% on 13.18x volume with RSI(7) extremely oversold at 17.0 and just 2.7% above its low; on a meme stock that volume is the risk, not the opportunity; sidelines.
Down 11.26% on 3.13x volume with RSI(7) extremely oversold at 16.2 and price through every moving average — a sharp decline with no identified catalyst; sidelines.
Up 7.46% and 14.3% on the week with RSI at 60.8 reclaiming the 50-day at $4.99 — but still 18% below the 200-day at $6.15 with no fundamental improvement; sidelines.
Up 1.87% but down 17.1% on the month with RSI weak at 39.6 and price below the 50-day at $919.23, as construction-equipment demand tracks fading infrastructure expectations; sidelines.
Up 4.44% and 14.5% on the week with RSI at 59.3 above every moving average — a marketing-tech small cap riding risk appetite without standalone logic; sidelines.
